Personalis, Inc. (NASDAQ:PSNL) CEO John Stephen West Sells 110,000 Shares

Personalis, Inc. (NASDAQ:PSNL) CEO John Stephen West sold 110,000 shares of Personalis stock in a transaction that occurred on Tuesday, June 8th. The shares were sold at an average price of $22.43, for a total transaction of $2,467,300.00. Following the sale, the chief executive officer now directly owns 670,520 shares of the company’s stock, valued at approximately $15,039,763.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of PSNL stock opened at $23.30 on Friday. The business’s fifty day simple moving average is $22.28. The firm has a market capitalization of $1.02 billion, a P/E ratio of -19.58 and a beta of 1.49. Personalis, Inc. has a 12-month low of $11.05 and a 12-month high of $53.46.

Personalis (NASDAQ:PSNL) last issued its quarterly earnings results on Wednesday, May 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Personalis had a negative return on equity of 21.21% and a negative net margin of 55.43%. On average, equities research analysts forecast that Personalis, Inc. will post -1.62 earnings per share for the current year.

PSNL has been the subject of a number of recent research reports. Morgan Stanley reduced their price objective on shares of Personalis from $38.00 to $35.00 and set an “overweight” rating for the company in a research note on Friday, May 7th. Oppenheimer raised shares of Personalis from a “market perform” rating to an “outperform” rating and set a $28.00 price objective for the company in a research note on Thursday, May 6th. Truist reduced their price objective on shares of Personalis from $37.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday, May 13th. Finally, Needham & Company LLC reduced their price objective on shares of Personalis from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Thursday, May 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $35.50.

Institutional investors and hedge funds have recently made changes to their positions in the company. NEXT Financial Group Inc purchased a new stake in shares of Personalis during the fourth quarter valued at $25,000. AdvisorNet Financial Inc purchased a new stake in shares of Personalis during the fourth quarter valued at $27,000. Penserra Capital Management LLC grew its holdings in shares of Personalis by 171.2% during the fourth quarter. Penserra Capital Management LLC now owns 895 shares of the company’s stock valued at $32,000 after buying an additional 565 shares during the last quarter. Banque Cantonale Vaudoise purchased a new stake in shares of Personalis during the fourth quarter valued at $33,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Personalis during the fourth quarter valued at $47,000. 67.53% of the stock is currently owned by hedge funds and other institutional investors.

About Personalis

Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.

Featured Story: Cost of Capital Explained

Insider Buying and Selling by Quarter for Personalis (NASDAQ:PSNL)

Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.